Macrogenics (MGNX) Cash from Restructuring (2012 - 2018)
Macrogenics (MGNX) posted quarterly Cash from Restructuring of -$298000.0 for Q1 2018, up 21.37% year-over-year from -$245526.1 in Q1 2017, and up 28.54% quarter-over-quarter from -$417000.0 in Q4 2017.
Macrogenics (MGNX) Cash from Restructuring (2012 - 2018) Analysis & Trends
Macrogenics (MGNX) has reported Cash from Restructuring for 7 consecutive years, with -$298000.0 the latest figure, recorded in Q1 2018.
- In Q1 2018, Cash from Restructuring rose 21.37% year-over-year to -$298000.0; the TTM figure through Mar 2019 stood at -$298000.0 (up 80.29% YoY), while the FY2017 annual figure was -$1.6 million, up 43.55% from the prior year.
- Cash from Restructuring advanced to -$298000.0 in Q1 2018 per MGNX's latest filing, from -$417000.0 in the prior quarter.
- Across five years, Cash from Restructuring topped out at -$298000.0 in Q1 2018 and bottomed at -$2.0 million in Q2 2015.
- Historically, Cash from Restructuring has averaged -$555588.2 across 5 years, with a median of -$392000.0 in 2017.
- Annual changes were most pronounced in 2015 — Cash from Restructuring plunged 459.72% — and 2017, when it soared 76.18%.
- Macrogenics' Cash from Restructuring stood at -$372000.0 in 2014, then retreated by 23.66% to -$460000.0 in 2015, then increased by 24.13% to -$349000.0 in 2016, then slipped by 19.48% to -$417000.0 in 2017, then rose by 28.54% to -$298000.0 in 2018.
- Business Quant data shows MGNX's Cash from Restructuring at -$298000.0 in Q1 2018, -$417000.0 in Q4 2017, and -$405000.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | -298,000.00 |
| Dec 31, 2017 | -417,000.00 |
| Sep 30, 2017 | -405,000.00 |
| Jun 30, 2017 | -392,000.00 |
| Mar 31, 2017 | -379,000.00 |
| Dec 31, 2016 | -349,000.00 |
| Sep 30, 2016 | -339,000.00 |
| Jun 30, 2016 | -1.65 Mn |
| Mar 31, 2016 | -488,000.00 |
| Dec 31, 2015 | -460,000.00 |
| Sep 30, 2015 | -450,000.00 |
| Jun 30, 2015 | -1.99 Mn |
| Mar 31, 2015 | -396,000.00 |
| Dec 31, 2014 | -372,000.00 |
| Sep 30, 2014 | -364,000.00 |
| Jun 30, 2014 | -355,000.00 |
| Mar 31, 2014 | -348,000.00 |
| Dec 31, 2013 | -163,000.00 |
| Sep 30, 2013 | -159,000.00 |
| Jun 30, 2013 | -155,005.00 |